Výsledky vyhľadávania - "SURPASS studies"

HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis

Autori: Tina Vilsbøll Maciej T. Malecki Palash Sharma a ďalší

Zdroj: Vilsbøll, T, Malecki, M T, Sharma, P, Thieu, V T, Chivukula, K K & Kiljanski, J 2025, ' HbA1c reduction with tirzepatide in people with type 2 diabetes : The contribution of weight loss assessed by a mediation analysis ', Diabetes, Obesity and Metabolism, vol. 27, no. 10, pp. 5498-5505 . https://doi.org/10.1111/dom.16592

Predmety: HbA1c, tirzepatide, SURPASS studies, weight-loss independent effects, weight loss, weight-loss dependent effects, mediation analysis

Popis súboru: application/pdf

Prístupová URL adresa: https://curis.ku.dk/ws/files/497406870/Diabetes_Obesity_Metabolism_-_2025_-_Vilsb_ll_-_HbA1c_reduction_with_tirzepatide_in_people_with_type_2_diabetes_The.pdf
https://ruj.uj.edu.pl/handle/item/559453
https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.16592

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program.

Autori: Lingvay I Mosenzon O Brown K a ďalší

Zdroj: Cardiovascular diabetology [Cardiovasc Diabetol] 2023 Mar 24; Vol. 22 (1), pp. 66. Date of Electronic Publication: 2023 Mar 24.

Spôsob vydávania: Journal Article; Research Support, Non-U.S. Gov't

Informácie o časopise: Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE

Výrazy zo slovníka MeSH: Diabetes Mellitus, Type 2*/diagnosis , Diabetes Mellitus, Type 2*/drug therapy , Hypotension*/chemically induced , Hypotension*/complications , Hypotension*/drug therapy, Humans ; Blood Pressure ; Antihypertensive Agents/adverse effects ; Gastric Inhibitory Polypeptide/therapeutic use ; Body Weight ; Weight Loss ; Hypoglycemic Agents/adverse effects ; Tirzepatide ; Glucagon-Like Peptide-1 Receptor Agonists